Answers are grounded in this paper and cite their sources.
Introduction: Endoscopic duodenal mucosal resurfacing (DMR) induces mucosal regeneration through hydrothermal ablation. Studies have shown that DMR improves hyperglycaemia in patients with type 2 diabetes. The INSPIRE study (n=16) aimed to eliminate insulin by combining DMR with a glucagon-like peptide-1 receptor agonist (GLP-1RA). At 18 months, 53% of patients were off insulin with adequate glycaemic control. This retrospective analysis evaluates long-term effects of DMR and GLP-1RA. Research design and methods: Fourteen patients gave consent for the prolonged follow-up and data on glycaemic control, medication and DMR satisfaction were obtained via general practitioners. Primary endpoint was the number of patients off insulin with glycaemic control (haemoglobin A1c (HbA1c) ≤58 mmol/mol (7.5%)) at 4 years post DMR. Secondary endpoints were changes in HbA1c, fasting plasma glucose (FPG), weight, body mass index (BMI), use of glucose-lowering medications, treatment satisfaction and willingness to undergo DMR retreatment. Results: Nine out of 14 patients (64%) were off insulin at 4 years. Of these, five patients (36% of study population) were adequately controlled. HbA1c and FPG did not change significantly, whereas BMI decreased at 3 and 4 years. Among the responders at 12 months, there was 80% durability at 4 years. Patients rated the DMR procedure 9 out of 10 and 86% were willing to undergo DMR retreatment. Conclusions: Despite a stable number of patients remaining off insulin, a decrease in patients with adequate glycaemic control was observed. This suggests a slightly fading long-term DMR effect on glycaemia. High patient satisfaction and willingness for DMR retreatment indicate a promising avenue for further research.
No takes yet. Share an insight, caveat, or question.
Busch et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: